A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) — ADHERE

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trial

Official title:
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status Completed

Clinical Trial Summary

This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Polyneuropathies
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Clinical Trial Details

NCT number	NCT04281472
Study type	Interventional
Source	argenx
Contact
Status	Completed
Phase	Phase 2
Start date	April 15, 2020
Completion date	May 11, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06040567` - Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
Active, not recruiting	`NCT04280718` - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)	Phase 2
Recruiting	`NCT05492604` - Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP.	N/A
Not yet recruiting	`NCT03166527` - Panzyga in CIDP Administered at Different Infusion Rates	Phase 3
Completed	`NCT02027701` - Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Phase 3
No longer available	`NCT05014724` - CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)